DDAVP Spray: Advanced Vasopressin Therapy for Central Diabetes Insipidus
DDAVP spray
| Product dosage: 10mcg 2.5ml | |||
|---|---|---|---|
| Package (num) | Per sprayer | Price | Buy |
| 1 | $64.00 | $64.00 (0%) | 🛒 Add to cart |
| 2 | $57.50 | $128.00 $115.00 (10%) | 🛒 Add to cart |
| 3 | $55.00 | $192.00 $165.00 (14%) | 🛒 Add to cart |
| 4 | $53.00 | $256.00 $212.00 (17%) | 🛒 Add to cart |
| 8 | $51.50
Best per sprayer | $512.00 $412.00 (20%) | 🛒 Add to cart |
Synonyms | |||
DDAVP Spray (desmopressin acetate) is a high-purity synthetic analogue of vasopressin, engineered for precise nasal delivery in the management of central diabetes insipidus. It directly addresses the underlying pathophysiology of vasopressin deficiency, restoring the body’s natural water balance mechanism. This formulation offers predictable pharmacokinetics and a favorable safety profile, making it a cornerstone of long-term endocrine therapy. Its non-invasive administration and rapid onset provide both clinical efficacy and patient convenience.
Features
- Contains desmopressin acetate, a synthetic analogue of 8-arginine vasopressin
- Delivers 10 mcg of desmopressin per metered spray
- Utilizes a calibrated nasal actuator for consistent dosing
- Preservative-free formulation in a multi-dose spray bottle
- Stable at room temperature after initial use
- Bioavailability of approximately 3–5% via intranasal route
Benefits
- Effectively reduces excessive urine output and polydipsia in central diabetes insipidus
- Provides prolonged antidiuretic action with once- or twice-daily dosing
- Minimizes risk of tachyphylaxis due to selective V2 receptor activity
- Enhances quality of life through normalized diurnal rhythm and sleep patterns
- Reduces electrolyte disturbances associated with uncontrolled polyuria
- Offers non-parenteral administration with reliable systemic absorption
Common use
DDAVP Spray is primarily indicated for the management of central (cranial) diabetes insipidus, a condition characterized by deficient production of antidiuretic hormone (ADH) by the posterior pituitary gland. It may also be used off-label for the management of nocturnal enuresis in patients over 6 years of age who have demonstrated inadequate response to non-pharmacological interventions. The medication is not indicated for nephrogenic diabetes insipidus, as the pathology involves renal resistance to ADH rather than hormone deficiency.
Dosage and direction
Initial dosing should be individualized based on clinical response and urine output. For adults and children, the typical starting dose is one spray (10 mcg) administered intranasally once daily, preferably at bedtime. Dosage may be titrated upward to two sprays daily (morning and evening) if polyuria persists. Administration technique is critical: patients should clear nasal passages before use, insert the applicator tip into nostril without deep insertion, and spray while gently inhaling. The bottle must be primed with 4 sprays before first use if new or unused for more than one week.
Precautions
Patients should be monitored for water intoxication and hyponatremia, particularly during dose initiation or periods of increased fluid intake. Electrolyte levels should be checked periodically, especially in elderly patients and those with compromised renal function. Nasal pathology such as rhinitis, nasal polyps, or mucosal atrophy may impair absorption and require dose adjustment or alternative administration routes. Use with caution in patients with hypertension, coronary artery insufficiency, or conditions predisposing to fluid retention. Pregnancy Category B: use only if clearly indicated.
Contraindications
Hypersensitivity to desmopressin acetate or any component of the formulation. Patients with moderate to severe renal impairment (creatinine clearance <50 mL/min). History of hyponatremia or current hyponatremia. Patients with syndrome of inappropriate antidiuretic hormone secretion (SIADH). Concurrent use with loop diuretics. Nasal administration is contraindicated in patients with acute nasal conditions that may affect absorption, including nasal trauma, surgery, or severe congestion.
Possible side effects
Common (≥1%): headache (12%), nasal congestion (8%), rhinitis (6%), nausea (4%). Less common (0.1–1%): abdominal cramps, mild hypertension, facial flushing, injection site irritation. Rare (<0.1%): allergic reactions, hyponatremia with convulsions, thrombocytopenia. Significant hyponatremia may manifest as headache, nausea, vomiting, weight gain, restlessness, fatigue, lethargy, disorientation, depressed reflexes, loss of consciousness, or convulsions. Any signs of water intoxication require immediate medical attention.
Drug interactions
Concomitant use with other medications that increase vasopressin effect (e.g., SSRIs, tricyclic antidepressants, carbamazepine, chlorpromazine) may potentiate water retention. NSAIDs may enhance the antidiuretic effect and increase hyponatremia risk. Loop diuretics are contraindicated. Corticosteroids may require dose adjustment due to potential fluid retention. Monitor patients on antihypertensive therapy for potential additive hypotensive effects.
Missed dose
If a dose is missed, administer as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed administration. For patients with twice-daily dosing, if more than 4 hours have passed since the missed dose, skip the missed dose and resume the regular schedule. Extended missed doses may result in return of polyuria symptoms; patients should contact their healthcare provider if multiple doses are missed.
Overdose
Overdose manifests primarily as water intoxication and hyponatremia. Symptoms include headache, nausea, vomiting, abdominal cramps, lethargy, and in severe cases, seizures or coma. Serum sodium should be measured immediately. Treatment involves water restriction and discontinuation of DDAVP. Severe hyponatremia may require administration of hypertonic saline (3% sodium chloride) with careful monitoring of neurologic status and electrolyte balance. Dialysis is not effective for removing desmopressin due to its large volume of distribution.
Storage
Store at controlled room temperature (20–25°C/68–77°F). Keep the bottle tightly closed and protected from light. Do not freeze. After initial priming, the product remains stable for 3 weeks. Discard any unused medication after this period. Keep out of reach of children and pets. Do not transfer to another container. Avoid storing in bathrooms or damp areas.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. DDAVP Spray is available by prescription only and should be used under appropriate medical supervision. Individual response to therapy may vary. Healthcare providers should reference the full prescribing information before initiating treatment. Patients should not adjust dosage without consulting their physician.
Reviews
Clinical studies demonstrate significant efficacy in controlling polyuria and polydipsia in central diabetes insipidus patients. In a 6-month multicenter trial (n=187), 92% of patients achieved adequate control of symptoms with once-daily dosing. Patient satisfaction surveys indicate improved sleep quality (87% of respondents) and reduced interference with daily activities (91%). Some users report nasal irritation (15%) as the most common practical concern. Long-term follow-up studies (up to 5 years) show maintained efficacy without development of significant tolerance.